Two Sigma Advisers LP Reduces Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Two Sigma Advisers LP trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 70.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 103,700 shares of the company's stock after selling 252,800 shares during the period. Two Sigma Advisers LP's holdings in Moderna were worth $4,312,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB increased its position in Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after acquiring an additional 587 shares during the period. Compass Planning Associates Inc bought a new stake in shares of Moderna during the fourth quarter worth $37,000. Venturi Wealth Management LLC grew its holdings in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after purchasing an additional 664 shares during the last quarter. Crowley Wealth Management Inc. bought a new position in Moderna during the 4th quarter worth approximately $41,000. Finally, Itau Unibanco Holding S.A. boosted its position in shares of Moderna by 51.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after purchasing an additional 343 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Trading Up 2.9%

Shares of NASDAQ MRNA traded up $0.75 during midday trading on Thursday, reaching $26.80. The company had a trading volume of 7,721,569 shares, compared to its average volume of 8,040,862. The business's 50-day simple moving average is $26.70 and its 200 day simple moving average is $34.14. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $158.82. The stock has a market cap of $10.36 billion, a P/E ratio of -2.89 and a beta of 1.99.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The firm had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. During the same quarter in the prior year, the business earned ($3.07) earnings per share. The business's quarterly revenue was down 35.3% compared to the same quarter last year. Analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current year.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of analyst reports. Barclays cut their price objective on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating on the stock in a report on Friday, May 2nd. UBS Group lowered their price objective on shares of Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Royal Bank of Canada reduced their target price on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. The Goldman Sachs Group lowered shares of Moderna from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Finally, Bank of America dropped their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Moderna currently has a consensus rating of "Hold" and an average target price of $53.58.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.